PDCD1 and hereditary clear cell renal cell carcinoma: Immune checkpoint inhibitors that target Programmed Cell Death-1 (PD-1; pembrolizumab and nivolumab) were initially licensed for use in metastatic melanoma, and are now approved for use in renal cell carcinoma and small cell lung cancer, with further trials underway.